Paparizos V A, Kyriakis K P, Mileounis K A, Pfandl-Polydorou D, Stavrianeas N G, Vareltzidis A G, Stratigos J D
Dept. of Dermatology, Andreas Sygros Hospital, University of Athens, Greece.
J Chemother. 1996 Oct;8(5):403-6. doi: 10.1179/joc.1996.8.5.403.
After administration of Adriamycin, bleomycin, vincristine (ABV) as palliative chemotherapy in advanced AIDS-related Kaposi's sarcoma (AIDS.KS) patients with low Karnosfsky performance scores, the authors attempted to estimate the overall biological cost/benefit relating to the disease. The authors analyzed data from 20 consecutive AIDS patients with advanced Kaposi's sarcoma presenting skin and visceral involvement treated with ABV every 3 weeks. An increased rate of infections, HIV and ABV-related side effects was observed. The performance amelioration (about 30%) was not significantly correlated with AIDS.KS clinical remission. CD4 count at baseline (p < 0.05), ABV therapy duration (p < 0.001), the achieved AIDS.KS clinical amelioration score (p < 0.01) and the improved Karnofsky score (p < 0.001) were significant predictors of life expectancy which was unrelated to the rate of side effects. The authors conclude that ABV palliative chemotherapy can assist in protracting life expectancy and improving the Karnofsky score.
在对卡氏评分较低的晚期艾滋病相关卡波西肉瘤（AIDS.KS）患者进行阿霉素、博来霉素、长春新碱（ABV）姑息化疗后，作者试图评估与该疾病相关的总体生物学成本/效益。作者分析了20例连续的晚期卡波西肉瘤艾滋病患者的数据，这些患者皮肤和内脏均受累，每3周接受一次ABV治疗。观察到感染率、HIV及ABV相关副作用有所增加。性能改善（约30%）与AIDS.KS临床缓解无显著相关性。基线时的CD4细胞计数（p < 0.05）、ABV治疗持续时间（p < 0.001）、达到的AIDS.KS临床改善评分（p < 0.01）和改善的卡氏评分（p < 0.001）是预期寿命的显著预测因素，而预期寿命与副作用发生率无关。作者得出结论，ABV姑息化疗有助于延长预期寿命并提高卡氏评分。
